Tormentic acid

Name: Tormentic acid
Brand: MedChemExpress
SKU: HY-N4137
Rating: 4.5 (1 reviews)

Cat. No.: HY-N4137 Purity: 98.38%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Tormentic acid, a triterpene isolated from Rosa rugosa, exerts anti-inflammatory, antihyperlipidemic, and anti-atherogenic properties.

For research use only. We do not sell to patients.

Tormentic acid Chemical Structure

CAS No. : 13850-16-3

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	Get quote
50 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Tormentic acid:

Tormentic acid (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Tormentic acid, a triterpene isolated from Rosa rugosa, exerts anti-inflammatory, antihyperlipidemic, and anti-atherogenic properties^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	IC₅₀	> 30 μM Compound: 1, tormentic acid	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22995818]
8505C	IC₅₀	23.4 μM Compound: 1, tormentic acid	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 22995818]
A253 cell line	IC₅₀	> 30 μM Compound: 1, tormentic acid	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22995818]
A2780	IC₅₀	> 30 μM Compound: 1, tormentic acid	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22995818]
A549	IC₅₀	31 μM Compound: 1, tormentic acid	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22995818]
A549	IC₅₀	62.36 μg/mL Compound: 2; TA	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 30108878]
Bel-7402	IC₅₀	54.22 μg/mL Compound: 2; TA	Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 30108878]
DLD-1	IC₅₀	31 μM Compound: 1, tormentic acid	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22995818]
H9	IC₅₀	15 μg/mL Compound: 9	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
HepG2	IC₅₀	40.57 μg/mL Compound: 2; TA	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 30108878]
K562	IC₅₀	89.36 μM Compound: 2	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 17889544]
MCF7	IC₅₀	24.23 μg/mL Compound: 2; TA	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30108878]
MCF7	IC₅₀	32.3 μM Compound: 1, tormentic acid	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22995818]
NIH3T3	IC₅₀	> 30 μM Compound: 1, tormentic acid	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22995818]
RAW264.7	IC₅₀	24.9 μM Compound: 14	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay	[PMID: 25245917]
SK-OV-3	IC₅₀	2.4 μM Compound: 20	Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM) Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM)	[PMID: 35500202]
SK-OV-3	IC₅₀	23.24 μM Compound: 20	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 35500202]

In Vitro

Tormentic acid inhibits LPS-induced iNOS, COX-2, and TNF-α expression through inactivation of the nuclear factor-κb pathway in RAW 264.7 macrophages^[1].
Tormentic acid suppresses high-fat diet-induced diabetes and hyperlipidemia by glucose transporter 4 and AMP-activated protein kinase phosphorylation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

488.70

Formula

C₃₀H₄₈O₅

CAS No.

13850-16-3

Appearance

Solid

Color

White to off-white

SMILES

OC([C@]12[C@]([C@](O)([C@H](C)CC2)C)([H])C3=CC[C@@]([C@@]4([C@@](C(C)([C@@H](O)[C@H](O)C4)C)([H])CC5)C)([H])[C@]5(C)[C@]3(C)CC1)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (102.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0462 mL	10.2312 mL	20.4625 mL
5 mM	0.4092 mL	2.0462 mL	4.0925 mL
10 mM	0.2046 mL	1.0231 mL	2.0462 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.38%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (254 KB) HNMR (426 KB) CNMR (458 KB) RP-HPLC (339 KB) MS (192 KB)

Handling Instructions (2659 KB)

References

[1]. An HJ, et al. Tormentic acid, a triterpenoid saponin, isolated from Rosa rugosa, inhibited LPS-induced iNOS, COX-2, and TNF-α expression through inactivation of the nuclear factor-κb pathway in RAW 264.7 macrophages. Int Immunopharmacol. 2011 Apr;11(4):504-10. [Content Brief]

[2]. Wu JB, et al. Tormentic acid, a major component of suspension cells of Eriobotrya japonica, suppresses high-fat diet-induced diabetes and hyperlipidemia by glucose transporter 4 and AMP-activated protein kinase phosphorylation. J Agric Food Chem. 2014 Nov 5;62(44):10717-26. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0462 mL	10.2312 mL	20.4625 mL	51.1561 mL
	5 mM	0.4092 mL	2.0462 mL	4.0925 mL	10.2312 mL
	10 mM	0.2046 mL	1.0231 mL	2.0462 mL	5.1156 mL
	15 mM	0.1364 mL	0.6821 mL	1.3642 mL	3.4104 mL
	20 mM	0.1023 mL	0.5116 mL	1.0231 mL	2.5578 mL
	25 mM	0.0818 mL	0.4092 mL	0.8185 mL	2.0462 mL
	30 mM	0.0682 mL	0.3410 mL	0.6821 mL	1.7052 mL
	40 mM	0.0512 mL	0.2558 mL	0.5116 mL	1.2789 mL
	50 mM	0.0409 mL	0.2046 mL	0.4092 mL	1.0231 mL
	60 mM	0.0341 mL	0.1705 mL	0.3410 mL	0.8526 mL
	80 mM	0.0256 mL	0.1279 mL	0.2558 mL	0.6395 mL
	100 mM	0.0205 mL	0.1023 mL	0.2046 mL	0.5116 mL

Tormentic acid Related Classifications

Inflammation/Immunology Cardiovascular Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tormentic acid13850-16-3OthersfatdiabetesphosphorylationglucosetransporterRAW 264.7macrophagesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tormentic acid

Customer Review

Other Forms of Tormentic acid:

Tormentic acid Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Tormentic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tormentic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report